Company Overview and News
Swarovski officially opens its doors in Sri Lanka bringing its heritage and craftsmanship in crystal to Colombo City Centre at No.137, Sir James Peiris Mawatha, Colombo 2. The brand brings its dazzling collection that delivers extraordinary everyday style to women around the world.
Softlogic partnered with Samsung to officially open its first branded Experience Store in Sri Lanka this week with a ribbon-cutting ceremony by Mr Ashok Pathirage, Chairman/Managing Director, Softlogic Holdings PLC & Mr Hanbae Park, Managing Director, Samsung Sri Lanka. The new Samsung experience store at 14 De Fonseka Place, Colombo 5 operates collaboratively with retail giant Softlogic Retail (Pvt.
Jun 15, 2018 (LBO) – Colombo Stock Exchange (CSE) has announced changes in S&P Sri Lanka 20 index constituents made by S&P Dow Jones Indices at the 2018 mid‐year index rebalance.
Softlogic Information Technologies Pvt Ltd, one of the country’s leading software and hardware solutions providers and a subsidiary of Softlogic Holdings PLC, conducted the latest in a series of events titled “The Future Enterprise” for its corporate customers at The Galadari Hotel recently. The event topic “Software Defined Data Center” intended to educate all corporate customers on the upcoming state-of-the-art technologies and innovations that Dell EMC is set to introduce to the market.
(PRESS RELEASE) – If summer is the season to get out there and make a statement, ODEL’s exciting summer collection is designed to set its shoppers apart in their choice of clothing and accessories.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CSE:SHL / SOFTLOGIC HOLDINGS PLC on message board site Silicon Investor.